Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Truist Securities analyst Srikripa Devarakonda has maintained a Buy rating on Axsome Therapeutics (NASDAQ: AXSM) and increased the price target from $200 to $285. This adjustment reflects a positive outlook for the company's performance.